decisionhealth Newsletters, Part B News - 2009 Issue 11 (November)
CMS reverses pay cut for Avastin
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS reversal involving Medicare payment handling for Avastin used in age-related macular degeneration (AMD). It is relevant to ophthalmology practices, Medicare billing staff, and revenue cycle teams that submit Part B claims for ocular drug administration and need to understand how the policy change affects reporting and claim reprocessing. The article focuses on the general payment-policy shift, the affected drug billing framework, and the operational impact on claims submitted during the brief change period.
Why This Topic Matters
It helps providers and billing staff recognize that a recent Medicare payment adjustment was reversed and that affected claims may need attention. The topic matters because temporary billing changes can affect reimbursement, claim submission workflows, and reprocessing activities.
What You Will Learn
- How a Medicare payment policy change affected Avastin billing for AMD
- Why the temporary HCPCS billing change was reversed
- What types of claims may need to be resubmitted or reprocessed
- How policy changes can affect ophthalmology reimbursement workflows
Who Should Read This
- Ophthalmologists
- Medical coders
- Billing specialists
- Revenue cycle staff
- Practice managers
- Medicare billing staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com